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Introduction 72
Thanks to an increased life expectancy, an improvement in health status and medical services, the older 73 population is constantly increasing. In 2015, 617 million (8.5%) people in the world were aged 65 and over 74 (older adults) and these numbers are estimated to rise to 1.6 billion by 2050 (1). Despite the increase in life 75 expectancy, there is no corresponding increase in healthy life expectancy: recent findings in 2015 show 76 that, despite a life expectancy at the age of 65 of 21.2 years for women and 17.9 years for men, only 9.4 77 years are healthy years (2). Concomitantly, health maintenance in older age will be one of the most 78 relevant societal challenges in the future years. Lifestyle changes appear to be fundamental in increasing 79 healthy life expectancy, and adequate nutrition is enormously important, given that malnutrition (i.e., 80 undernutrition), particularly as protein-energy deficit is very common amongst the elderly population. This 81 is due to the effects of aging per se that causes decreased salivation, difficulty swallowing, and delayed 82 emptying of the stomach and oesophagus, as well as slower gastrointestinal movement (3). Other 83 conditions associated with aging, such as drug use, loneliness, depression, lack of oral health, low quality of 84 life, in addition to chronic non-communicable diseases, markedly increase the undernutrition risk (4). It has 85 been estimated that undernutrition affects between 20 and 50% of hospitalised patients (5) and 5 and 10% 86 of patients living at home in the community (6), the great variations reported in different studies depends 87 not only to differences in the population analysed, but also on the adopted definition. Recently a large 88 study (7) , that applies harmonized criteria to define malnutrition in different clinical settings and 89 population, shows a great underestimation of the problem and confirms higher prevalence of malnutrition 90 in residents of nursing homes and hospitalized patients evaluated by Mini Nutritional Assessment test 91 (MNA) . Malnutrition is more prevalent in patients affected by acute and chronic disorders with reduced 92 functional status (7) and is associated with poor clinical outcomes and prognosis. Malnutrition is associated 93 with reduced immune function, anaemia, impaired cognitive function, and higher hospitalisation rate and is 94 a strong independent predictor of mortality [for a review, see A. Granic et al, 2018 (8) ]. Malnutrition causes 95 body weight loss and muscle atrophy, decreased muscle strength and function, impaired balance, and 96 increased fall and fall-related injuries. The malnutrition-linked muscle atrophy accelerates transition to 97 frailty (9) and has been considered as one of the determinants of sarcopenia (10, 11) . Importantly, 98 sarcopenia is defined as low muscle mass, with defective muscle strength (also named dynapenia) and 99 decline of physical performance (12) and is, per se, associated with increased morbidity and mortality (13) . 100
Although several guidelines and consensus documents on nutritional care of malnourished elderly subjects 101 have been proposed (14) , and protein needs established in the range from 0.8 g/kg/day (healthy adults) 102 and up to 1.5 g/kg/day (in some cases even higher) according to age, disease and degree of protein 103 depletion (15), the daily protein consumption in older subjects is often inadequate and undernutrition and 104 sarcopenia are underestimated and considered as one of the factors of aging (4, 7) . 105
It has been suggested that the aging process significantly affects protein metabolism and enhances the 106 muscle wastage that accompanies undernutrition and sarcopenia. Some studies show lower plasma 107 concentrations of branched-chain amino acids (BCAAs) in elderly subjects (16, 17) , whereas others do not 108 (18, 19) . This may be due to the increased first-pass splanchnic extraction of amino acids in older people, 109 with a consequent decrease in delivery to the skeletal muscle tissue and availability for muscle tissue 110 anabolism (20) . Most kinetics studies show no difference in the ability of older subjects to retain and 7 patients received a consecutive number after enrolment and were subsequently allocated to randomization 139 list, according with Kim et al (32) . The randomisation was carried out by the principal investigator, scientists 140 performing lab measurement and statistical analyses were blind to treatment. 141
The inclusion criterion was malnutrition defined as MNA lower than 17. The MNA test is composed of 18 142 items that can be completed in less than 10 minutes. It provides a multidimensional assessment of senior 143 patients nutritional status taking into account four domains: anthropometry, general status, dietary habits, 144 and self-perceived health and nutrition states. Anthropometry includes the measurement of calf and arm 145 circumferences, Body Mass Index (BMI), calculated after the measurement of weight and height, and 146 questions about weight loss (4 items); general status comprehends 7 questions related to general health, 147 medication and mobility; the assessment of dietary habits comprehends 5 questions on the number of 148 meals, food and fluid intake and autonomy of feeding; 2 questions evaluate self-perceived health and 149 nutrition states (33, 34) . 150
Exclusion criteria were known malignancy, life expectancy of less than two months, heart failure (NYHA IV), 151 end stage renal disease, liver cirrhosis (Child B-C), tube/percutaneous endoscopic gastrostomy feeding or 152 parenteral nutrition, Mini-Mental State Examination (MMSE)≤18 and MNA>17. MMSE ≥ 18 identifies 153 patients with mild form of cognitive impairment, those patients generally do not have problems in 154 swallowing and are able to take drugs. We evaluated for inclusion 336 malnourished patients presenting to 155 our out-patients service for a geriatric evaluation, the evaluation was done by expert geriatricians, of the 156 evaluated patients 181 were excluded for presence of exclusion criteria; one hundred and fifty-five 157 malnourished elderly patients living at home in the community and who were admitted to the outpatients' 158 department of our Unit were enrolled. Patients were evaluated at baseline and randomised to receive diet 159 advice, summarised in an easy-to-use brochure for lay persons (77 patients) or to BCAAem supplements (78 160 patients, Aminotrofic®, kindly supplied by Errekappa Euroterapici S.p.A. and Professional Dietetics S.p.A, 2 161 sachets/day). Aminotrofic® is a BCAA enriched mixture, it contains Leucine (1,250 mg), Lysine (650 mg), 162 8 Vitamin B1 (0.15 mg). We suggested the patients to take the BCAAem in the mid-morning and afternoon, 165 regardless of food ingestion. In order to check the compliance we asked the patients to bring back at center 166 the empty sachets at follow-up visit. 167
Diet advice comprised general advice on the meaning and consequences of malnutrition and dietary 168 recommendation based on the principle of "Food First" to maximize the patient nutritional intake from 169 regular food and drink according with the ESPEN Guidelines on Enteral Nutrition for geriatric patients (35) . 170
According to the "Food First" approach we suggested the patients to increase the frequency of eating, 171 maximize the nutrient and energy density of food and drink and fortify food with the addition of fats and 172 sugars, suggested recommendations were given to the patients both orally by the physician and by the use 173 of a brochure; provided dietary recommendations are summarized in the Supplementary Table 1 . 174
Period of patient enrolment: February 2013-September 2017. Patients were called back to the centre and 175 all the measurements were performed after 1 and 2 months. 116 patients completed the study (60 treated 176 with BCAAem and 56 with diet advice). In the BCAAem group, 2 patients died after the first month, 1 was 177 admitted to hospital within the first month, 10 patients did not return for the month-1 visit and 5 patients 178 did not return for the month-2 visit for personal reasons. In the diet advice group, 1 patient died during the 179 first month, 2 patients did not return for the month-1 visit since they were hospitalised, 14 patients did not 180 return for the month-1 visit and 4 patients for the month-2 visit for personal reasons, there were no 181 collateral effects. Only data from patients with complete follow up were included in the statistical analyses 182 ( Fig. 1) . 183 The main outcome measures were muscle mass, strength and performance and mitochondrial ATP 189 production; secondary measurements were cognitive performance, nutritional status, health perceived 190 status, mitochondrial biogenesis and activity in peripheral blood mononuclear cells (PBMCs). The 191 measurements were carried out at baseline and after 1 and 2 months of treatment. 192 Clinical assessment. 193 Global clinical assessment: Self-sufficiency was measured by assessing the Katz Index of Activity of Daily 194 Living (ADL), which evaluates overall performance in six functions: bathing, dressing, going to toilet, 195 transferring, continence and feeding; cognitive performance was evaluated by MMSE that is a brief test 196 used to routinely track cognitive changes in an individual both cognitively intact or with severe cognitive 197 impairment over time. Patients' mood was evaluated by the short form of Geriatric Depression Scale (GDS), 198 the scale consists of 15 questions related to the patient's mood answered "yes" or "no". The cut-off point 199 adopted to define a patient as depressed is a GDS higher than 7 (36). Perceived health status was measured 200 by asking the patients to answer the question "How is your health in general?". The patients' answers: 201 "very good", "good", "fair", "bad" or "very bad" were rated from 5 (Very good) to 1 (Very bad), although 202 there is not yet full standardisation of the measurement of perceived health status across Organisation for 203 Cumulative Index Rating Scale (CIRS) was also recorded, this scale accounts for both the presence and the 207 severity of co-morbidities (38). 208
Nutritional status assessment: We assessed patients' dietary intake using the PROGEO software (Progeo 209 S.r.l., Italy), it provides an extensive food database and allows to record and to accurately estimate 210 patients' average nutritional intake. The Photo Intake tool helps patients to recognize the amount of food 211 by the visual weight method, ingested showing pictures of food in 3 portions, food quantities can also be 212 recorded as conventional standard units (spoon, glass, cup, etc.) . The software provides a large food 213 database and automatically displays patients' average daily calories and nutrients intake. The interview was 214 based on the recall method on 7 days making reference to the "standard week" as suggested by the 215 using a plicometer (Mahr GMBH Esslingen), the Pollock, Schmidt and Jackson's formula on three sites 219 (triceps, subscapular and abdomen) was applied (39, 40) . Skinfold thickness measurements were performed 220 by trained staff according to standard technique: the skinfold thickness was measured by lifting a fold of 221 skin and subcutaneous fat away from the underlying muscle and bone, the skinfold thickness was measured 222 in duplicate with the plicometer. When a difference between the first and the second measurement 223 exceeded 6 mm, a third measurement was taken. The plicometer is applied 1cm from the ridge of skin; take 224 reading 3 seconds after application, to standardise any effects produced by deformation of tissues. The 225 triceps skinfold was measured at the back of the left arm, midway between the acromial process of the 226 scapula and the olecranon process of the ulna. The subscapular skinfold is picked up just under the lower 227 angle of the scapular lifted horizontally below the tip of right scapula. The abdominal skinfold was lifted 228 diagonal midway between umbilicus and right anterior superior iliac spine. 229
Muscle mass, strength and performance: Appendicular muscle mass was measured using arm and calf 230 circumference. Arm circumference was measured in duplicate to the nearest 0.001 m at a point midway 231 between the lateral projection of the acromion process of the scapula and the inferior margin of the 232 olecranon process of the ulna. The mean of the two measurements was used in the analyses. The calf 233 circumference was measured to the nearest 0.001 m on the left leg with the participant standing straight, 234 feet 20 cm apart, body weight equally distributed on both feet and at the level of the widest circumference 235 of the calf; measurements were taken according to the Longitudinal Aging Study Amsterdam (LASA -236 http://www.lasa-vu.nl/themes/physical/anthropometry.htm). 237
Muscle strength was measured via the hand grip test, using a hydraulic hand dynamometer (MSD, Europe) 238 (41) to assess muscle performance and mobility the Timed Up and Go (TUG) test, 30 seconds Chair Sit to 239 Stand (30-s CST) test and the 4 meters gait speed test were performed. 240
TUG is a simple test used to assess a person's mobility and requires both static and dynamic balance. TUG is 241 performed by measuring the time that the patient takes to rise from a chair, walk three meters, turn 242 around, walk back to the chair and sit down. TUG performed in ten seconds or less indicate normal 12 seconds means that the person needs assistance outside and indicates further examination and 245 intervention. A score of 30 seconds or more suggests that the person may be prone to falls (42). The 30-s 246 CST allows the evaluation of lower body strength and to assess the fatigue effect due to the number of sit-247 to-stand repetitions. It is performed with a chair without arms, the patient seated in the middle of the chair 248 with the arms crossed over his/her chest, then is instructed to stand up as quickly as possible safely without 249 using his/her arms. The number of stands the patients completed in 30 seconds is manually recorded (43). 250
The 4-meter gait speed test was performed using a stopwatch and measures the time, in seconds, the 251 patients take to complete a 4-meter walk. 252
The risk of falls further was evaluated using the Tinetti Gait and Balance Instrument as follows: to test the 253 patient's balance, the patient has to sit in a hard, armless chair and is asked to rise and stay standing, then 254 turn 360° and sit back down. Next, the patient walks a few meters at a normal speed, turns, walks back and 255 sits down. The evaluator observes several features and scores the patient's performance: the higher the 256 score, the better the performance. The maximum score for Gait is 12 points, while the maximum for 257
Balance is 16 points, with a total maximum for the overall Tinetti Instrument of 28 points. Score 258
Interpretation: <19 high risk of falls, 19-28 low risk of falls. 259
Laboratory tests. 260
Functional evaluation of mitochondrial activity: In order to isolate mitochondrial fractions, blood cells were 261 washed twice in ice-cold PBS, then lysed in 0.5 mL buffer A (50 mMTris, 100 mMKCl, 5 mM MgCl2, 1.8 mM 262 ATP, 1 mM EDTA, pH 7.2), supplemented with protease inhibitor cocktail III (Calbiochem), 1 mM PMSF and 263 250 mMNaF. Samples were clarified by centrifuging at 650×g for 3 min at 4°C, and the supernatant was 264 collected and centrifuged at 13000×g for 5 min at 4°C. This supernatant was discarded and the pellet 265 containing mitochondria was washed in 0.5 mL buffer A and suspended in 0.25 mL buffer B (250 mM 266 sucrose, 15 mM K2HPO4, 2 mM MgCl2, 0.5 mM EDTA, 5% w/v BSA). A 50 µL aliquot was sonicated and used 267 for the measurement of protein content, as reported in Campia et al, 2009 (44) ; the remaining part was 268 diluted to a protein concentration of 10 µg/µL and stored at −80°C until the use. The activity of Complex I-269 III was measured on 10 µL of non-sonicated mitochondrial samples (44), suspended in 0.59 mL buffer C (5 mM KH2PO4, 5 mM MgCl2, 5% w/v BSA). Then 0.38 mL buffer D (25% w/v saponin, 50 mM KH2PO4, 5 mM 271
MgCl2, 5% w/v BSA, 0.12 mM cytochrome c-oxidized form, 0.2 mM NaN3) was added for 5 min at room 272 temperature. The reaction was started with 0.15 mM NADH and was followed for 5 min. The absorbance 273 was read using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments, Winooski, VT). Results 274 were expressed as nmol reduced cytochrome C/min/mg mitochondrial proteins. In each experimental set, 275 the complex I inhibitor rotenone (100 µM) was added as an internal negative control. In the presence of 276 rotenone, the electron flux was reduced to below 5%. 277
The amount of ATP was measured on 20 µg of mitochondrial extracts using the ATP Bioluminescent Assay 278 Kit (FL-AA, Sigma Aldrich Co., St. Louis, MO). Data were converted into nmol/mg mitochondrial proteins, 279 using a previously set calibration curve. 280
Under these experimental conditions, the rate of cytochrome C reduction, expressed as nmol cytochrome C 281 reduced/min/mg cell protein, was dependent on the activity of both Complex I and Complex III. Red cells were lysed in all peripheral blood samples, total nucleated cells were collected and dissolved in 287
TRIzol reagent (TRISure, Bioline Reagents Ltd, UK) and frozen at -80 °C until RNA extraction. RNA was 288 isolated using chloroform extraction and subsequent isopropanol precipitation according to the 289 manufacturer's protocol. 1 g of RNA was reverse-transcribed to single-stranded cDNA using the SensiFAST 290 cDNA Synthesis Kit (Bioline Reagents Ltd, UK). RT-PCR was performed using the SensiFAST SYBR Hi-ROX Kit 291 (Bioline Reagents Ltd, UK). The housekeeping control gene was -actin, and gene expression was quantified 292 using the 2 -Ct method. The primers used (Invitrogen, California, USA) are shown in Supplementary Table  293 2. 294
All the lab experiments were performed in duplicate, data presented are averages of the duplicates. The 295 coefficient of variation intra-operator ranges between 0.03 and 1.00 for all the measurements. 296
Statistical analyses: The sample size was calculated on both clinical and lab outcomes; amongst clinical 300 outcome muscle mass was used; in particular sample size provide an 85% power (p<0.05), 50 patients per 301 group have to be enrolled to detect a difference (alpha error = 0.05) of at least 2% variation in muscle mass, 302 based on a study on the effect of BCAAs administration on muscle mass and performance in humans (45). 303
As the patients were old and frail we assumed a possible 35% of drop out at the follow-up. In order to 304 calculate sample size for lab tests we considered as significant an increase of 1.5 fold in ATP production as 305 shown by D'Antona et al with BCAAem in aged mice (28), data on ATP production in humans by PBMCs 306 derives from Avis et al (46) based on this analyses sample size was calculated to provide 95% power 307 (p<0.05) to detect a 1.5-fold difference in ATP production was 13 patients per group . 308
All the analysed variables were tested for normality by the kurtosis test, TUG, 30-s CST, 4 meters walking 309 test, TBARs, electron flux were non-Gaussian. 310
To evaluate possible differences between patients treated with BCAAem or diet advice at baseline the 311 patients were compare by one-way ANOVA for Gaussian variables and by the Mann-Whitney U test for 312 non-Gaussian ones. Gender was compared amongst patients treated with BCAAem or diet adviceby χ2 test. 313
The effect of treatment was evaluated per protocol using the two-way ANOVA for repeated measurements 314 for Gaussian variables, non-Gaussian variables were evaluated after logarithmic transformation. To 315 evaluate possible influences of mitochondrial function on muscle and cognitive performance six linear 316 regression models (GLM) were fitted, between ATP and electron flux and TUG, 30-s CST, Tinetti and 4 317 meters walking test, hand grip and MMSE, non-Gaussian variables were logarithmically transformed. 318 SPSS 24.0 were used for the analyses and p<0.05 was considered statistically significant. Patients treated with BCAAem or diet advice were comparable for all the clinical variables analysed, this 329 excludes possible selection bias that could influence our results ( Supplementary Table 3 ). Compliance to 330
BCAAem was good, none of the patients have a compliance lower than 75%, the compliance ranges 331 between 75% and 90%. 332
Treatment significantly improves general health and cognitive performance. 333
Patients' general health measured by perceived health status equally improved in both treatment groups 334 and significantly correlated with nutritional status (MNA: R=0.50, p<0.0001; fat percentage: R=0.26, 335 p=0.005) at the end of the follow-up period. Also, the mood measured by GDS significantly improved. The 336 level of independence was not significantly influenced by treatment. 337
Patients' overall cognitive performance measured by MMSE significantly improved in patients treated with 338 BCAAem, not in patients treated with diet advice; MMSE significantly correlated with MNA (R=0.28, 339 p=0.002) as well as GDS (R=-0.32, p<0.0001) at the end of the follow-up period ( Table 1) . 340
Treatment significantly improves nutritional status. 341
Patients adhered to the dietary recommendation as shown by the increased caloric intake. Caloric intake 342 increased in both groups and was particularly consistent in the group treated with diet advice, where 343 dietary recommendations were reinforced by the use of an easy-to-use illustrated brochure, in this group also protein intake was significantly higher. During treatment, we observed a significant improvement in Muscle mass measured by calf and arm circumferences significantly increased in both groups as well as 348 muscular strength measured by hand grip strength ( Table 3) . 349
To evaluate whether muscular performance was influenced by treatment, we performed the TUG, the 30-s 350 CST test to evaluate both performance and resistance to fatigue. Muscular performance improved with 351 treatment as did muscle mass. Risk of falls was measured using the Tinetti scale and the TUG, mobility was 352 measured using the 4-meter gait speed test, these tests improved equally in the two groups ( Table 3) . 353
BCAAem improve bioenergetic capacity of PBMCs. 354
Here we show that ATP production and electron flux significantly increased over time only in mitochondria 355 from patients treated with BCAAem, and that BCAAem maintain oxidative stress at baseline values, 356 whereas, in patients treated with diet advice, oxidative stress increased over time ( Table 4 ). 357
To model the relationship between mitochondria stimulation on PBMCs and effects of BCAAem or diet 358 advice on muscular and cognitive performance we applied a linear regression approach. 359
Our data showed that mitochondrial ATP production significantly predicts balance measured by Tinetti 360 after 2 months of treatment and 4 meters walking test after 1 month of treatment ( Table 5) . MMSE is 361 significantly predicted by ATP after 1 month and by electron flux after 2 months of treatment ( Table 6) . 362
We also evaluated the effect of BCAAem treatment on some of the main mitochondrial biogenesis and 363 fusion markers. Our data showed that treatment increases the expression of COX-1 and COX-4 and TFAM, 364
whereas NRF-1 shows only a non-significant trend towards the increase, significant differences versus 365 baseline levels were measured only in patients treated with BCAAem. The expression of MFN-1 and MFN-2 was increased although not significantly by treatment; in the BCAAem treated patients we observed an 367 increased expression of these two molecules after one month of therapy (Table 7) . 368 369
Discussion 370
As life expectancy increases, adequate nutrition is fundamental for successful aging, here, we confirm that 371 amelioration of nutritional status is associated with improvement in general health status, muscle and 372 cognitive performance in old malnourished patients, and show that this may be due to an improvement of 373 their mitochondrial bioenergetics profile and decreasing oxidative stress. 374
Here we show that the diagnosis of malnutrition and its treatment, albeit using different approaches, is 375 fundamental in improving patients' general health and nutritional status. Indeed, in both our treatment 376 groups, there was an improvement in MNA, and weight gain, however the increase in caloric and protein 377 intake was higher in patients treated only with diet advice; the use of this approach instead of the use of an 378 isonitrogenous mix of non-essential aminoacids with a double blind design may be considered as a 379 limitation of the study, however the use of the "food first" approach underlines the role of the physician's 380 counselling in patients' adherence to diet. Another possible limitation of the study is the use of a "non-381 standard" recall method for diet evaluation, here we use a recall on the 7 days before the interview as our 382 old patients usually follow a standard diet with little variation day by day, the evaluation of 7 days allow us 383 to make a more comprehensive evaluation asking the patients "what is your usual meal (breakfast, lunch, 384 dinner and snacks)? Do you change your meal during one week? If yes when and how during the previous 385
week?". The improvement in cognitive performance, measured by MMSE, was significant in patients taking 386 BCAAem supplements: indeed, patients treated with BCAAem gain, on average, 1.2 points of MMSE. This 387 result is in accordance with a previous study in a cohort of patients with severe chronic obstructive 388 pulmonary disease. However, in this study, the increase in cognitive performance was associated with 389 improved pulmonary gas exchange and there was no mechanistic explanation (47). The effect of the 390 administration of BCAAs in cognitive function was also previously assessed in severely brain damaged patients with hepatic encephalopathy or traumatic brain injuries: in these patients, intravenous BCAAs 392 improve consciousness, assessed using the Glasgow Coma Scale and performance, assessed using the 393 Disability Rating Scale. However, no cognitive tests were performed in these studies and the underlying 394 mechanism was not investigated (48) (49) (50) (51) (52) . A mechanistic explanation has been provided by the study of 395 animal models of brain injury, demonstrating the efficacy of dietary supplementation with BCAAs in 396 promoting cognitive performance, by restoring hippocampal function, given that BCAAs act as glutamate 397 and GABA precursors (53). In humans, a recent, very large retrospective study showed an association 398 between serum level of isoleucine, leucine and valine with a lower risk of dementia. This study does not 399 report any causal mechanism (54). 400
Poor nutrition and, in particular, protein-energy deficit further accelerate the loss of muscle mass and 401 function associated with age: sarcopenia (55,56). Sarcopenia increases the risk of falls, disability, frailty, loss 402 of independence and death increasing healthcare costs (57, 58) . Here, we show that intervention on 403 malnutrition can improve muscle mass and performance. In particular, we show an improvement in 404 balance by the Tinetti balance test and the TUG test, with a consequent reduction of the risk of falls and 405 fall-related injuries in a population with increased risk of falls (average TUG higher than 14 seconds). 406
Treatment increases muscle performance, increasing mobility, and resistance to fatigue; the improved 407 performance in the 4-meter gait speed test observed during treatment demonstrates an overall increase in 408 health and the performance status of the patients according to previous study (62). Also, muscle strength 409 measured using hand dynamometer increased in both treatment groups. 410
Taken together, these data demonstrate that dietary intervention can counteract the decrease in physical 411 and cognitive performance in old malnourished patients and that loss of muscle mass and function can be 412 countered using an appropriate treatment strategy in a rapidly aging population. 413
Several studies suggest a major role of mitochondrial dysfunction as a major contributor to aging and age-414 related diseases [for a review, see Cedikova et al, 2016 (63) ]. Mitochondrial biogenesis, ATP production and study, we further investigate the mechanisms underlying the better clinical effects obtained with the 418 administration of BCAAem, besides diet advice, by evaluating the treatment effects on mitochondrial 419 function, biogenesis and fusion, as well as oxidative stress. In animal models, the administration of BCAAs 420 has been shown to be effective in increasing the number and the function of mitochondria (28). In a small 421 cohort of young healthy obese and non-obese subjects, the infusion of a mixture of aminoacids increased 422 ATP production rates of muscular mitochondria in lean, but not in obese subjects (64). The increase in size, 423 number and energy production of mitochondria that follows the administration of BCAAem was associated 424 with better muscle performance, on both at skeletal and cardiac muscle level in mice (28). Here we 425 evaluated mitochondria from PBMCs, it has been previously shown that mitochondria isolated from 426 skeletal muscle and from PBMCs have a similar bioenergetics profile and are associated with gait speed in 427 older adults (65), as regards neurological tissues other authors measured mitochondrial function in PBMCs 428 and correlates its reduction with neurodegeneration (66). According with these observations we show that 429 mitochondrial activity measured using ATP production and electron flux increase is associated with both 430 cognitive and muscular performance amelioration in elderly patients; these data are particularly interesting 431 as they suggest a possible non-invasive and reliable measure to follow up treatment outcomes. We show 432 that the increase of TFAM, mitochondrial respiratory chain (COX-1 and COX-4) and mitofusin gene 433 expressions correlate with an increase in ATP production and electron flux, and suggest that BCAAem 434 treatment induces biogenesis, activity and fusion of mitochondria, stimulating at the end the bioenergetic 435 capacity of PBMCs. Electronflux 2 months* 0.05±0.02 2.5 0.014 0.01 to 0.09 Table 7 . Mitochondria biogenesis and fusion at baseline and follow-up according to treatment. The table  703 shows multiple T-test and Two-way ANOVA for multiple measure results. Values are shown as mean ± SE 704 and 95% CI of the difference between basal, 1 and 2 months of treatment. 705 * Denotes differences between baseline and 1 month; ** Denotes differences between baseline and 2 706 months; $ Denotes differences between 1 and 2 months; Significant values are in bold. 707 708 
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